Related Experiment Videos
Presence and location of TP53 mutation determines pattern of CDKN2A/ARF pathway inactivation in bladder cancer
1Department of Biochemistry and Molecular Biology, USC/Norris Comprehensive Cancer Center, University of Southern California, School of Medicine, Los Angeles 90033, USA.
Abstract:
Transformation and immortalization require the inactivation of key cell cycle regulatory genes. We examined 19 bladder cancer cell lines derived from 17 patients for alterations in TP53, RB1, CDKN2A, and ARF. Twelve cell lines had a mutation in exons 5-11 of TP53 and, with only one exception, a concomitant loss of RB1 protein expression. Another group of seven cell lines had a wild-type TP53 gene or a mutation in exons 1-4 of TP53 and concomitant alterations in both CDKN2A and ARF in every case. This demonstrates the requirement, in all but one line, for inactivation of both the CDKN2A/RB1 and ARF/TP53 pathways in bladder cancer cell lines and provides the first evidence for potential differences in the penetrance of mutations in the transactivation and DNA-binding domains of TP53.
Insights
Bladder cancer cell lines require inactivation of cell cycle genes like TP53 and RB1, or CDKN2A and ARF, for transformation. This study reveals distinct genetic pathway alterations in bladder cancer progression.
Area of Science:
- Oncology
- Molecular Biology
- Genetics
Background:
- Cell cycle regulatory genes are crucial for preventing uncontrolled cell proliferation.
- Inactivation of key genes like TP53, RB1, CDKN2A, and ARF is essential for cellular transformation and immortalization in cancers.
Purpose of the Study:
- To investigate alterations in TP53, RB1, CDKN2A, and ARF in 19 bladder cancer cell lines.
- To understand the roles of these genes in bladder cancer development and progression.
Main Methods:
- Analysis of 19 bladder cancer cell lines from 17 patients.
- Examination of genetic alterations and protein expression for TP53, RB1, CDKN2A, and ARF.
Main Results:
- Twelve cell lines showed TP53 mutations (exons 5-11) with concurrent RB1 protein loss.
- Seven cell lines exhibited wild-type or early-mutation TP53 alongside alterations in both CDKN2A and ARF.
- Demonstrated inactivation of CDKN2A/RB1 and ARF/TP53 pathways in most bladder cancer cell lines.
Conclusions:
- Bladder cancer cell lines necessitate the inactivation of either the CDKN2A/RB1 or the ARF/TP53 pathways.
- Provides evidence for differential mutation penetrance in TP53's transactivation versus DNA-binding domains.